β-Boswellic Acid Suppresses Breast Precancerous Lesions via GLUT1 Targeting-Mediated Glycolysis Inhibition and AMPK Pathway Activation

Fengjie Bie, Guijuan Zhang, Xianxin Yan, Xinyi Ma, Sha Zhan, Yebei Qiu, Jingyu Cao, Yi Ma, Min MaFrontiers in Oncology 2022 · DOI

Abstract: Breast carcinoma is a multistep progressive disease. Precancerous prevention seems to be crucial. β-Boswellic acid (β-BA), the main component of the folk medicine Boswellia serrata (B. serrata), has been reported to be effective in various diseases including tumors. In this work, we demonstrated that β-BA could inhibit breast precancerous lesions in rat disease models. Consistently, β-BA could suppress proliferation and induce apoptosis on MCF-10AT without significantly influencing MCF-10A. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis suggested that β-BA may interfere with the metabolic pathway. Metabolism-related assays showed that β-BA suppressed glycolysis and reduced ATP production, which then activated the AMPK pathway and inhibited the mTOR pathway to limit MCF-10AT proliferation. Further molecular docking analysis suggested that GLUT1 might be the target of β-BA. Forced expression of GLUT1 could rescue the glycolysis suppression and survival limitation induced by β-BA on MCF-10AT. Taken together, β-BA could relieve precancerous lesions in vivo and in vitro through GLUT1 targeting-induced glycolysis suppression and AMPK/mTOR pathway alterations. Here, we offered a molecular basis for β-BA to be developed as a promising drug candidate for the prevention of breast precancerous lesions.

Introduction

Breast cancer is a complex, multistep disease that often begins with the development of precancerous lesions. While early detection and intervention are critical, current pharmacological options for prevention, such as Tamoxifen, are often avoided by patients due to significant side effects, including increased risks of blood clots and endometrial cancer. Consequently, there is a pressing clinical need for safer, naturally derived chemopreventive agents.

This study, published in Frontiers in Oncology, explores the potential of $\beta$-Boswellic acid ($\beta$-BA)—the primary bioactive component of Frankincense (Boswellia serrata)—to halt the progression of breast cancer by targeting the unique metabolic requirements of precancerous cells.

The Warburg Effect: A Precancerous Vulnerability

A defining characteristic of malignant cells is the Warburg Effect, where cells preferentially utilize glycolysis for energy production even in oxygen-rich environments. The researchers hypothesized that this metabolic shift occurs early in the transition from normal to cancerous tissue. By comparing normal-like (MCF-10A), precancerous (MCF-10AT), and cancerous (MDA-MB-231) cell lines, they confirmed that precancerous cells already exhibit an increased reliance on glucose fermentation for survival and growth.

Mechanism: Targeting the GLUT1 "Gatekeeper"

Using bioinformatics tools and molecular docking simulations, the team identified the glucose transporter GLUT1 as the primary target of $\beta$-BA. The docking analysis revealed that $\beta$-BA binds to the active site of GLUT1 with a binding energy of -10.5 kcal/mol, which is significantly higher than the affinity of GLUT1 for its natural substrate, glucose (-6.9 kcal/mol).

This physical blockade prevents glucose from entering the cell, leading to a rapid decline in intracellular glucose levels and a subsequent drop in ATP production. This "energy crisis" is sensed by the enzyme AMPK (AMP-activated protein kinase). Once activated, AMPK acts as a metabolic brake, shutting down the mTOR (mammalian target of rapamycin) pathway—the cell's primary engine for growth and protein synthesis—thereby inducing apoptosis (programmed cell death) in the precancerous cells.

Experimental Validation and Selectivity

A critical finding of the study was the high therapeutic index of $\beta$-BA. As shown in the experimental data, $\beta$-BA significantly inhibited the viability and colony-forming capacity of precancerous and cancerous cells while leaving healthy MCF-10A cells largely unaffected.

β-BA structure and its selective inhibitory effects on cell viability and colony formation across normal (MCF-10A), precancerous (MCF-10AT), and cancerous (MDA-MB-231) cell lines.

To confirm that GLUT1 was indeed the critical target, the researchers performed a "rescue" experiment. By forcing the overexpression of GLUT1 in MCF-10AT cells, they were able to counteract the inhibitory effects of $\beta$-BA, proving that the compound's efficacy is directly tied to its ability to block glucose transport.

In Vivo Efficacy

The study also validated these findings in a rat model of breast precancerous lesions induced by the carcinogen DMBA and hormonal stimulation. Topical treatment with a $\beta$-BA cream reduced the incidence of lesions to 44.2%, a result comparable to the 36.6% incidence observed in the Tamoxifen-treated group. This demonstrates that $\beta$-BA can effectively suppress lesion development in a complex biological system.

Conclusion and Future Outlook

$\beta$-Boswellic acid represents a promising candidate for breast cancer chemoprevention. By selectively targeting the metabolic "engine" of precancerous cells through GLUT1 inhibition, it offers a mechanism-driven approach to stopping cancer before it fully develops. Future research will need to address the systemic bioavailability of $\beta$-BA and ensure its safety profile regarding glucose transport in other vital tissues, such as the brain and red blood cells, before moving into human clinical trials.

Summary updated

Abstract

Breast carcinoma is a multistep progressive disease. Precancerous prevention seems to be crucial. β-Boswellic acid (β-BA), the main component of the folk medicine <i>Boswellia serrata</i> (<i>B. serrata</i>), has been reported to be effective in various diseases including tumors. In this work, we demonstrated that β-BA could inhibit breast precancerous lesions in rat disease models. Consistently, β-BA could suppress proliferation and induce apoptosis on MCF-10AT without significantly influencing MCF-10A. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis suggested that β-BA may interfere with the metabolic pathway. Metabolism-related assays showed that β-BA suppressed glycolysis and reduced ATP production, which then activated the AMPK pathway and inhibited the mTOR pathway to limit MCF-10AT proliferation. Further molecular docking analysis suggested that GLUT1 might be the target of β-BA. Forced expression of GLUT1 could rescue the glycolysis suppression and survival limitation induced by β-BA on MCF-10AT. Taken together, β-BA could relieve precancerous lesions <i>in vivo</i> and <i>in vitro</i> through GLUT1 targeting-induced glycolysis suppression and AMPK/mTOR pathway alterations. Here, we offered a molecular basis for β-BA to be developed as a promising drug candidate for the prevention of breast precancerous lesions.
BibTeX
@inproceedings{bie2022boswellic,
  author = {Fengjie Bie and Guijuan Zhang and Xianxin Yan and Xinyi Ma and Sha Zhan and Yebei Qiu and Jingyu Cao and Yi Ma and Min Ma},
  title = {{β-Boswellic Acid Suppresses Breast Precancerous Lesions via GLUT1 Targeting-Mediated Glycolysis Inhibition and AMPK Pathway Activation}},
  booktitle = {Frontiers in Oncology},
  year = {2022},
  doi = {10.3389/fonc.2022.896904},
}
Figure